XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Development Liability - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended
May 13, 2024
May 31, 2024
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jan. 31, 2020
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Proceeds from credit facility             $ 365,454,000    
Loss on extinguishment of development liability             1,949,000    
Interest expense     $ 12,532,000   $ 7,310,000   28,857,000 $ 22,179,000  
Sixth Financing Agreement [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Proceeds from credit facility $ 326,500,000 $ 326,500,000              
SFJ Agreement [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Proceeds from SFJ agreement           $ 140,000,000      
Payment made under agreement       $ 94,000,000          
Loss on extinguishment of development liability             1,900,000    
Interest expense     0   $ 6,400,000   8,900,000 $ 19,500,000  
Development liability reacquisition price     326,500,000       326,500,000    
Development liability carrying value     $ 324,600,000       $ 324,600,000    
SFJ Agreement [Member] | Regulatory Approval Granted US Food and Drug Administration [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Obligated to pay initial payment                 $ 460,000,000